USING GLUCOSAMINE FOR ARTHRITIS? LITTLE EVIDENCE OF BENEFIT, BUT A NEW REASON FOR CONCERN

Millions of people take glucosamine supplements hoping to relieve arthritis pain or protect their joints. But what if a supplement with little convincing evidence of benefit also carries a risk of harm?.

A 2026 study published in Nature Metabolism raises the disturbing possibility that glucosamine use may be associated with faster progression of dementia.

Before spending money on glucosamine, it is worth examining both sides of the risk-benefit equation.

Glucosamine has been studied extensively. Although some studies report modest improvements in pain and joint function, the more rigorous, independently funded trials generally find no clinically meaningful benefit compared with placebo. Although some favorable findings involve a particular prescription formulation of glucosamine sulfate, these results are controversial and from industry-sponsored research. The American College of Rheumatology strongly recommends against glucosamine.

The new safety concern comes from researchers studying abnormalities in glycosylation, a normal cellular process in which sugar molecules are attached to proteins. Excessive glycosylation was found in the brains of patients with Alzheimer's disease and increased with disease severity.

In animal studies on Alzheimer's-like disease, reducing glycosylation improved cognitive performance, while giving glucosamine worsened it. Based on this worry, researchers examined medical records from more than 66,000 patients. Glucosamine use was associated with a 25% higher likelihood of progressing from mild cognitive impairment to dementia.

These findings are concerning, but do not prove that glucosamine causes dementia or accelerates its progression. The human data were observational, meaning that differences between people taking glucosamine and those not taking it could have influenced the results. And animal findings do not necessarily translate into human disease.

The question is “why take it?” For people with osteoarthritis, glucosamine offers little convincing evidence of meaningful pain relief, improved function, or protection against progressive joint damage. And now there is a potentially important concern about cognitive harm, particularly in people with existing cognitive impairment or dementia.

The evidence does not justify claiming that glucosamine causes Alzheimer's disease. But when the expected benefit is negligible and a serious potential risk has emerged, the balance becomes difficult to defend. This alone is a good reason to reconsider whether the supplement is worth taking.

References

Hyperglycosylation is a metabolic driver of Alzheimer's disease.
https://pmc.ncbi.nlm.nih.gov/articles/PMC13303091/

Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis: a systematic review and individual patient data meta-analysis from the OA trial bank.
https://pubmed.ncbi.nlm.nih.gov/28754801/

2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee.
https://doi.org/10.1002/art.41142

VA/DoD Clinical Practice Guideline for the Non-Surgical Management of Hip & Knee Osteoarthritis.
https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/OA/Osteoarthritis-CPG_2026-Guideline_final_20260618.pdf

Glucosamine for osteoarthritis.
https://www.cochrane.org/evidence/CD002946_glucosamine-osteoarthritis